SCHEMBL15465668

SCHEMBL15465668

Cn1nccc1C1=CCC(C)(C)CC12OCCO2

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.34
COMT P21964 1/20 0.34
LATS1 O95835 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15464939 0.79 COMT (0.36) CYP17A1COMTLATS1
SCHEMBL15465205 0.72 CYP17A1 (0.35) CYP17A1COMTLATS1
SCHEMBL15464848 0.66 CYP17A1 (0.41) CYP17A1COMTLATS1
SCHEMBL15464807 0.65 BUB1 (0.36) CYP17A1COMTLATS1
SCHEMBL13920696 0.64 HDAC4 (0.36) CYP17A1COMTLATS1
SCHEMBL15950989 0.63 COMT (0.60) COMTLATS1
SCHEMBL18089098 0.61 COMT (0.32) COMT
SCHEMBL15464813 0.57 HDAC4 (0.40) CYP17A1COMTLATS1
SCHEMBL240197 0.55 CYP1A2 (0.49) COMT
SCHEMBL19356930 0.55 CYP1A2 (0.53) COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2974730-B1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO CO LTD (JP) 2018-01-31 EP disclosed
EP-3144300-B1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES DAIICHI SANKYO CO LTD (JP) 2017-12-20 EP disclosed
US-9845313-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-12-19 US disclosed
EP-3144300-A1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES Daiichi Sankyo Company, Limited (JP) 2017-03-22 EP disclosed
US-9597330-B2 Drugs for treating respiratory diseases DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-03-21 US disclosed
US-20170001984-A1 CYCLOALKANE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-01-05 US disclosed
US-9493448-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-11-15 US disclosed
EP-2813491-B1 CYCLOALKANE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-11-02 EP disclosed
US-20160038486-A1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-11 US disclosed
EP-2974730-A1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-20 EP disclosed
EP-2813491-A1 CYCLOALKANE DERIVATIVE Daiichi Sankyo Co., Ltd. (JP) 2014-12-17 EP disclosed
US-8889741-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-18 US disclosed
US-20140045862-A1 Cycloalkane Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038486-A1 DRUG FOR RESPIRATORY DISEASES SCN1B, NHERF1, SCNN1A CYP17A1 1212/4885COMT 3656/4885LATS1 4016/4885
US-20170001984-A1 CYCLOALKANE DERIVATIVES TRPV1, TRPA1, SCNN1A CYP17A1 2473/4885COMT 4364/4885LATS1 2917/4885
US-20140045862-A1 Cycloalkane Derivatives TRPV1, TRPA1, SCNN1A CYP17A1 2473/4885COMT 4364/4885LATS1 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.